Management View
- CEO Timothy Danker opened the call by highlighting that "SelectQuote executed well over the first quarter and is well positioned for a successful fiscal 2026." Danker noted consolidated revenue of $329 million, representing 13% growth over the same period a year ago, primarily driven by strong growth in Healthcare Services. He explained, "Our senior revenues were $59 million compared to $93 million a year ago. The decline was driven by lower policy production, which was expected given the new SEP parameters we foreshadowed on last quarter's call." Danker stated that the Senior business performed as expected in a "unique year-over-year compare for SEP."
- The CEO detailed a headwind in Healthcare Services EBITDA caused by a change in drug reimbursement rates with a SelectRx PBM partner, impacting the first half of the fiscal year by approximately $20 million. He said, "We now expect second quarter adjusted EBITDA for Healthcare Services to be approximately breakeven."
- Danker emphasized that "while we no longer anticipate reaching our $50 million target for fiscal '26, our confidence and visibility in the long-term economics of Healthcare Services are unchanged."
- Danker reiterated the company plans to exit the fiscal year at an annualized EBITDA run rate in the $40 million to $50 million range.
- CFO Ryan Clement stated, "Consolidated revenue grew 13% to $329 million, driven primarily by our SelectRx and Life Insurance business, which helped offset the unique comparison in Senior related to SEP." Clement added, "Our Senior EBITDA loss of $21 million was in line with our expectations given the production and investment dynamics I just spoke about. LTVs have remained relatively stable despite increased policyholder volatility in the past year, coming in at an average of 883 for the last 12 months."
Outlook
- The company reaffirmed fiscal 2026 financial outlook of $1.65 billion to $1.75 billion in revenue and $120 million to $150 million in adjusted EBITDA. Management indicated, "We plan to update our outlook following our fiscal second quarter as we will have additional detail on the AEP period for our Senior business."
- Danker remarked, "We remain confident today that we will be operating cash flow positive during fiscal year 2026."
- The company no longer anticipates reaching its $50 million EBITDA target for Healthcare Services in fiscal 2026 due to the short-term reimbursement headwind, but expects rates to revert to normalized levels on January 1, 2026.
Financial Results
- Consolidated revenue for the quarter was $329 million, with Senior revenues at $59 million and negative EBITDA of $21 million for the Senior segment. Danker explained that "quarterly EBITDA of negative $32 million was below our guided $25 million to $30 million loss range communicated on the last call due to the SelectRx margin dynamics."
- Healthcare Services experienced a near-term EBITDA margin impact, with the majority of the $20 million reimbursement hit expected in Q2. Clement commented, "Members held steady compared to last quarter, in line with expectations, given the first fiscal quarter is typically a slower one for onboarding SelectRx members."
- Life Insurance business revenues expanded nearly 20% in the quarter. Clement explained, "The lack of pull-through to our EBITDA...was also driven indirectly by the changes to this year's SEP."
Q&A
- Michael Murray, RBC Capital Markets, Research Division: On SelectRx, you seem to believe the reimbursement headwind is going to be contained in 2025. What gives you comfort that rates will improve next year? And is there a potential that you'll see a similar reimbursement headwind at the end of next year? Danker responded that the company is "absorbing a short-term impact in Q1, Q2, but the long-term economics remain very attractive. They don't change our perspective on growth or margin profile. As we work towards this new agreement, we will provide enhanced visibility and predictability into the growing business."
- Michael Murray, RBC: Could this [SelectRx improving MA member retention] have a potential positive impact on LTV? Clement answered, "We do see an improvement in the overall persistency when someone is a member of SelectRx and has a Medicare Advantage plan...We don't actually build that into the lifetime values themselves. So we're not booking that increase, but it's absolutely something we're observing."
- Patrick McCann, NOBLE Capital Markets: With regards to helping policyholders understand their plans better to focus more on retention, could you talk a little bit more about what that looks like in practice? Danker replied, "Protecting our back book of business is a priority. We've taken several actions, several learnings from last year and feel like we've got a jump start on it." William Grant, COO, elaborated, "We believe that we have a really good strategy to continue to offer our value proposition to consumers as we move along, and that we're targeting or talking to the right folks that need our help."
- Patrick McCann, NOBLE: Regarding research on social determinants of health, how is that informing your strategy? Danker noted, "We just want to understand our customer base better and better. That's really informed the products that we've picked from the healthcare side of the house." Grant added, "We have over 2.5 million Healthcare Select members...We have a variety of products within that now. It's ever expanding."
- Logan (for George Sutton), Craig-Hallum Capital Group: Any market differences in AEP relative to last year? Danker stated, "It's still very early, but we feel very prepared in the early days, a lot more innings to play out." Grant observed, "Every carrier pulled back to a certain degree...to really focus on profitability, which does create a lot of calls and education."
- Logan: On SelectRx growth and profitability focus, how will you manage the funnel through busy quarters? Grant said, "We're very focused on profitability and members that need the service the most mixed with PBMs and payers that appreciate the service the most."
Sentiment Analysis
- Analysts’ tone was cautiously probing, especially around the SelectRx reimbursement headwind and sustainability of relationships with PBMs, as well as the impact of SelectRx on LTV. There was a focus on the durability of the company’s guidance and the practical effects of short-term headwinds.
- Management’s tone in prepared remarks was confident, but in Q&A shifted to a more measured and slightly defensive stance, emphasizing “we have a very strong relationship” and “we're confident we'll reach a mutually beneficial agreement.” Danker stated, “We are absorbing a short-term impact...but the long-term economics remain very attractive.”
- Compared to the previous quarter, management’s tone became slightly more cautious due to near-term headwinds, while analysts maintained a similar level of skepticism and focus on risk.
Quarter-over-Quarter Comparison
- Guidance for fiscal 2026 revenue ($1.65 billion to $1.75 billion) and adjusted EBITDA ($120 million to $150 million) was reaffirmed, but the outlook for Healthcare Services EBITDA was revised downward due to a PBM reimbursement headwind.
- The previous quarter’s call projected Healthcare Services EBITDA would exceed $50 million for fiscal 2026; this quarter, management stated, “we no longer anticipate reaching our $50 million target for fiscal '26.”
- Strategic focus remains on high retention, agent productivity, and cash flow, but there is increased emphasis on navigating near-term reimbursement challenges.
- Analysts’ focus this quarter was more on the sustainability of PBM agreements and SelectRx profitability, while last quarter’s focus included margin scaling and technology investments.
- Management’s confidence remains in long-term strategy, but there is more explicit discussion of risk and mitigation steps.
Risks and Concerns
- Management cited a PBM reimbursement rate change as a challenge, with a $20 million impact recognized mainly in Q2. Danker stated, “We are actively negotiating a longer-term reimbursement agreement with this carrier that creates better visibility for both parties.”
- The company is addressing elevated policyholder volatility in the Senior segment due to industry-wide plan changes.
- There is an ongoing need to manage member retention and recapture rates amid dynamic market conditions.
- Management discussed strategic prioritization of profitability in SelectRx and the need for stable longer-term contracts with PBM partners.
Final Takeaway
SelectQuote’s management underscored a strong start to fiscal 2026, with revenue growth led by Healthcare Services and Life Insurance, but acknowledged a significant short-term EBITDA headwind in Healthcare Services due to a PBM reimbursement rate change. While the company reaffirmed its full-year revenue and adjusted EBITDA outlook, it no longer expects Healthcare Services to reach its original EBITDA target this year. Management remains confident in the long-term prospects for SelectRx and the company’s cash generation, highlighting ongoing negotiations to secure more predictable reimbursement rates and a continued focus on agent retention, operational leverage, and policyholder engagement to support future growth.
Read the full Earnings Call Transcript
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.